PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6700613

A path probability model for sister-chromatid exchanges induced by alkylating agents.

M K Conner·M Cheng·J A Biegel
View original source ↗Export metadata ↓

Abstract

A path probability model is described for evaluation of sister-chromatid exchanges (SCEs) induced by alkylating agents following treatment of G1 cells at the beginning of the first or second cycles of BrdUrd incorporation, or during G1 corresponding to an exact cell-cycle interval preceding BrdUrd incorporation. Algebraic expressions are derived for calculations of expected induced SCE frequencies (over baseline levels) in second and third (reciprocal and nonreciprocal SCEs) division cells for the described treatment protocols. The derivations take into consideration: p, the probability of a specific lesion inducing an SCE; rn, the extent of repair within the nth post-treatment cycle; and X, the number of lesions induced. Expressions are also derived for expected ratios of single: twin exchanges in endoreduplicated or tetraploid cells.

Explore related subjects

Alkylating AgentsBromodeoxyuridineCell CycleCrossing Over, GeneticDNA RepairDNA ReplicationModels, BiologicalMutagenicity TestsProbabilitySister Chromatid ExchangeJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M K Conner, M Cheng, J A Biegel. 1984. A path probability model for sister-chromatid exchanges induced by alkylating agents.. https://doi.org/10.1016/0027-5107(84)90167-2

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

Transgenic systems in studies on genotoxicity of alkylating agents: critical lesions, thresholds and defense mechanisms.

Transgenic systems, both cell lines and mice with gain or loss of function, are being used in order to modulate the expression of DNA repair proteins, thus allowing to assess their contribution to the defense against genotoxic mutagens and carcinogens. In this review, questions have been addressed concerning the use of transgenic systems in elucidating critical primary DNA lesions, their conversion into genotoxic endpoints, low-dose effects, and the relative contribution of individual cellular functions in defense. It has been shown that the repair protein alkyltransferase (MGMT) is decisive for protection against methylating and chloroethylating compounds. Protection pertains also to tumor formation, as revealed by the response of MGMT transgenic and knockout mice. Overexpression of genes involved in base excision repair (N-methylpurine-DNA glycosylase, apurinic endonuclease, DNA polymerase beta) is in most cases not beneficial in increasing the protection level, whereas their down-modulation or inactivation increases cellular sensitivity. This indicates that non-repaired base N-alkylation lesions and/or repair intermediates possess genotoxic potential. Modulation of mismatch repair and poly(ADP)ribosyl transferase has also been shown to affect the cellular response to alkylating agents. Furthermore, the role of Fos, Jun and p53 in cellular defense against alkylating mutagens is discussed.

Alkylating Agents↗
PubMed1998

Regulation of expression of the DNA repair gene O6-methylguanine-DNA methyltransferase via protein kinase C-mediated signaling.

O6-Alkylguanine is the major mutagenic and cytotoxic DNA lesion induced by alkylating agents, including 2-chloroethyl-N-nitrosourea-based antitumor drugs. This lesion is repaired by O6-methylguanine-DNA methyltransferase (MGMT), the expression of which is highly variable in both normal tissues and in tumor cells. The promoter of the human MGMT gene was found to contain two putative activator protein (AP)-1 sites. Here, we show that the level of MGMT mRNA in HeLa S3 cells was increased 3-5-fold by phorbol-12-myristate-13-acetate (TPA) and 1,2-diacyl-sn-glycerol (DAG), which are activators of protein kinase C (PKC), as well as by okadaic acid, an inhibitor of protein phosphatases. The PKC inhibitor 1-(5-isoquinoline sulfonyl)-2-methylpiperazine-HCl eliminated MGMT activation by TPA and DAG but not by OA. Prior down-regulation of PKC abolished subsequent effects of TPA or DAG. The results indicate AP-1 to be involved in regulation of MGMT expression. This hypothesis was supported by showing AP-1 binding to two target sequences of the MGMT promoter and transactivation of the MGMT promoter upon cotransfection with c-fos and c-jun in F9 cells. That TPA-mediated induction of MGMT caused increased cellular resistance to 2-chloroethyl-N-nitrosourea suggests a therapeutic significance for PKC-mediated MGMT modulation.

Alkylating Agents↗
PubMed1998

Critical steps in alkylation-induced aberration formation.

The process leading to chromosomal aberrations as a consequence of DNA damage is probably best understood for simple alkylating agents. Various functions have been identified which are involved in the conversion of critical primary lesions to aberrations. O6-methylguanine is considered to be an important critical preclastogenic DNA lesion, which is converted to aberrations in conjunction with faulty mismatch repair. It operates at sites of O6-methylguanine-thymine mispairing, leading to not yet defined secondary lesions. It is proposed that these secondary lesions cause DNA replication inhibition, which triggers recombination (sister-chromatid exchange formation) and is a critical event involved in aberration production in the second post-treatment replication cycle. For N-alkylations, DNA replication inhibition may result from depurinations and base excision repair intermediates causing a block of replication. In consequence, sister-chromatid exchanges as well as chromosomal aberrations are formed in the first post-treatment replication cycle. Data are available to show that DNA replication inhibition and aberration production in the first post-treatment replication cycle are interrelated.

Alkylating Agents↗